Oxford Biomedica (LON:OXB) Share Price Breaks Below 50 Day Moving Average – Here’s What Happened

Oxford Biomedica plc (LON:OXB – Get Free Report) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of GBX 515.39 and traded as low as GBX 502.05. Oxford Biomedica shares last traded at GBX 513, with a volume of 263,782 shares traded.

Wall Street Analysts Forecast Growth

OXB has been the topic of several recent research reports. Jefferies Financial Group restated a “buy” rating and set a GBX 827 target price on shares of Oxford Biomedica in a research report on Monday, October 26th. Royal Bank Of Canada restated an “outperform” rating and issued a GBX 900 price objective on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Finally, Deutsche Bank reaffirmed a “hold” rating and set a GBX 595 price objective on shares of Oxford Biomedica in a research note on Wednesday, September 2nd. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Oxford Biomedica currently has an average rating of “Moderate Buy” and a consensus target price of GBX 818.

Check Out Our Latest Stock Report on OXB

Oxford Biomedica Price Performance

The company has a debt-to-equity ratio of 273.08, a quick ratio of 1.67 and a current ratio of 2.21. The firm has a 50-day moving average price of GBX 516.20 and a 200 day moving average price of GBX 583.98. The stock has a market capitalization of £588.47 million, a P/E ratio of -15.16 and a beta of 1.11.

Oxford Biomedica (LON:OXB – Get Free Report) last announced its quarterly earnings data on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. On average, analysts expect that Oxford Biomedica plc will post -31.08 EPS for the current year.

Insiders Place Their Bets

In other Oxford Biomedica news, insider Roch Doliveux purchased 20,250 shares of the stock in a transaction on Wednesday, September 23rd. The stock was acquired at an average cost of GBX 505 per share, with a total value of £102,262.50. 43.30% of the stock is owned by corporate insiders.

About Oxford Biomedica

(Get Free Report)

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.

Further Reading

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.